These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

122 related articles for article (PubMed ID: 24772750)

  • 1. Angiotensin receptor blockers - advantages of the new sartans.
    Sabbah ZA; Mansoor A; Kaul U
    J Assoc Physicians India; 2013 Jul; 61(7):464-70. PubMed ID: 24772750
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Clinical profiles of new angiotensin II receptor blockers: telmisartan, olmesartan medoxomil, and irbesartan].
    Ishii M
    Nihon Rinsho; 2004 Jan; 62(1):193-202. PubMed ID: 14737853
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Optimal therapeutic strategy for treating patients with hypertension and atherosclerosis: focus on olmesartan medoxomil.
    Mason RP
    Vasc Health Risk Manag; 2011; 7():405-16. PubMed ID: 21796255
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Preventing cardiovascular events with angiotensin II receptor blockers: a closer look at telmisartan and valsartan.
    Volpe M
    Expert Rev Cardiovasc Ther; 2012 Aug; 10(8):1061-72. PubMed ID: 23030295
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparison of effects of olmesartan and telmisartan on blood pressure and metabolic parameters in Japanese early-stage type-2 diabetics with hypertension.
    Nakayama S; Watada H; Mita T; Ikeda F; Shimizu T; Uchino H; Fujitani Y; Hirose T; Kawamori R
    Hypertens Res; 2008 Jan; 31(1):7-13. PubMed ID: 18360012
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Efficacy and duration of action of the four selective angiotensin II subtype 1 receptor blockers, losartan, candesartan, valsartan and telmisartan, in patients with essential hypertension determined by home blood pressure measurements.
    Nishimura T; Hashimoto J; Ohkubo T; Kikuya M; Metoki H; Asayama K; Totsune K; Imai Y
    Clin Exp Hypertens; 2005 Aug; 27(6):477-89. PubMed ID: 16081340
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The ONTARGET/TRANSCEND Trial Programme: baseline data.
    Sleight P
    Acta Diabetol; 2005 Apr; 42 Suppl 1():S50-6. PubMed ID: 15868120
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Telmisartan is a promising cardiometabolic sartan due to its unique PPAR-gamma-inducing property.
    Yamagishi S; Takeuchi M
    Med Hypotheses; 2005; 64(3):476-8. PubMed ID: 15617852
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Choosing an angiotensin-receptor blocker: blood pressure lowering, cardiovascular protection or both?
    Neldam S
    Future Cardiol; 2010 Jan; 6(1):129-35. PubMed ID: 20014992
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Telmisartan and cardioprotection.
    Akhrass PR; McFarlane SI
    Vasc Health Risk Manag; 2011; 7():677-83. PubMed ID: 22140319
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Olmesartan medoxomil: recent clinical and experimental acquisitions.
    Destro M; Preti P; D'Ospina A; Christian Achiri NN; Ricci AR; Cagnoni F
    Expert Opin Drug Metab Toxicol; 2009 Sep; 5(9):1149-57. PubMed ID: 19689219
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antihypertensive, insulin-sensitising and renoprotective effects of a novel, potent and long-acting angiotensin II type 1 receptor blocker, azilsartan medoxomil, in rat and dog models.
    Kusumoto K; Igata H; Ojima M; Tsuboi A; Imanishi M; Yamaguchi F; Sakamoto H; Kuroita T; Kawaguchi N; Nishigaki N; Nagaya H
    Eur J Pharmacol; 2011 Nov; 669(1-3):84-93. PubMed ID: 21816148
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of telmisartan on the inflammatory state in patients with coronary atherosclerosis--influence on IP-10, TNF-α and MCP-1.
    Klinghammer L; Urschel K; Cicha I; Lewczuk P; Raaz-Schrauder D; Achenbach S; Garlichs CD
    Cytokine; 2013 May; 62(2):290-6. PubMed ID: 23541900
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Angiotensin II receptor blocker-based therapy in Japanese elderly, high-risk, hypertensive patients.
    Ogawa H; Kim-Mitsuyama S; Matsui K; Jinnouchi T; Jinnouchi H; Arakawa K;
    Am J Med; 2012 Oct; 125(10):981-90. PubMed ID: 22503610
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Efficacy of renin-angiotensin system (RAS) blockers on cardiovascular and renal outcomes in patients with type 2 diabetes.
    Cao Z; Cooper ME
    Acta Diabetol; 2012 Aug; 49(4):243-54. PubMed ID: 21947383
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recent progress in the treatment of cardiovascular disease using olmesartan.
    Miura S; Saku K
    Clin Exp Hypertens; 2014; 36(7):441-6. PubMed ID: 24164503
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hypertension treatment and implications of recent cardiovascular outcome trials.
    Weber MA
    J Hypertens Suppl; 2006 Apr; 24(2):S37-44. PubMed ID: 16601560
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of olmesartan medoxomil in patients with stage 1 hypertension: blood pressure lowering and goal achievement.
    Wilford Germino F
    Postgrad Med; 2010 Nov; 122(6):57-67. PubMed ID: 21084783
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Reduction of proteinuria with angiotensin receptor blockers.
    Galle J
    Nat Clin Pract Cardiovasc Med; 2008 Jul; 5 Suppl 1():S36-43. PubMed ID: 18580865
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Does the angiotensin receptor blocker telmisartan prevent morbid atherosclerotic events?
    Cohn JN
    Nat Clin Pract Cardiovasc Med; 2008 Sep; 5(9):526-7. PubMed ID: 18665135
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.